Great Lakes develops and commercializes products designed to prevent infections associated with indwelling catheters.

OmniComm will build and host the study for Great Lakes by deploying TrialMaster for electronic data capture.

By using OmniComm’s proprietary eLearning system, the company will also train more than 60 site users for the study and will work with Great Lakes and many clinical research organizations to manage the clinical trial by using EDC technology.

OmniComm Systems chief executive officer Krzysztof Applet said: "Great Lakes Pharmaceuticals chose TrialMaster because it is a very straight-forward, configurable system with robust reporting capabilities."